The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
The anti‐apoptotic genes Bcl‐XL and Bcl‐2 are over‐expressed and contribute to chemoresistance of non‐proliferating leukaemic CD34+ cells
Abstract
Summary. In acute myeloid leukaemia (AML), cell kinetic quiescence has been postulated to contribute to drug resistance. As the anti‐apoptotic genes Bcl‐2 and Bcl‐X L have been implicated in cell cycle regulation, we investigated the expression of these genes in non‐proliferating (Q) and proliferating (P) AML and normal CD34+ progenitor cells. Using reverse transcription polymerase chain reaction, Bcl‐X L and Bcl‐2 were overexpressed in Q versus P AML cells, whereas no difference in Bcl‐X S and Bax expression was found. Furthermore, the Bcl‐X L/X S but not the Bcl‐2/Bax ratio was higher in Q AML compared with normal CD34+ Q cells (P = 0·001). An inverse correlation between Bcl‐2 expression of leukaemic Q cells and their ability to enter the cell cycle was found. Treatment with all‐trans retinoic acid (ATRA) reduced Bcl‐2 and Bcl‐X L expression in the leukaemic Q cells, and enhanced their chemosensitivity to cytosine arabinoside (ara‐C). These findings demonstrate overexpression of the anti‐apoptotic proteins Bcl‐X L and Bcl‐2 in quiescent CD34+ AML cells and suggest their involvement in the chemoresistance. The observed inverse correlation between Bcl‐2 and proliferation suggests a role for Bcl‐2 in the cell cycle regulation of AML. These findings could be used in the development of therapies that selectively induce apoptosis in quiescent leukaemic progenitor cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two CD95 (APO‐1/Fas) signaling pathways
Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K. J., Debatin, K., Krammer, P. H., & Peter, M. E. (1998) · The EMBO Journal · doi:10.1093/emboj/17.6.1675 · Cited by 3,000
Expression of bcl-xL can confer a multidrug resistance phenotype
Minn, A., Rudin, C., Boise, L., & Thompson, C. (1995) · Blood · doi:10.1182/blood.v86.5.1903.bloodjournal8651903 · Cited by 415 · cited 1×
“…the Bcl-2 protein and its close homologue Bcl-XL confer resistance to cytotoxic drug-induced damage (Kamesaki et al, 1993; Walton et al, 1993; Minn et al, 1995) and, not surprisingly, leukaemic cells with autonomous growth characteristics produce high levels of Bcl-2 and Bcl-XL (Bradbury et…”
Background
Cited by
Mechanisms of chemoresistance in cancer stem cells
Abdullah, L. N., & Chow, E. K. (2013) · Clinical and Translational Medicine · doi:10.1186/2001-1326-2-3 · Cited by 721
Tibes, R., Qiu, Y., Lu, Y., Hennessy, B., Andreeff, M., Mills, G. B., & Kornblau, S. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0334 · Cited by 718
Self-citationSamudio, I., Harmancey, R., Fiegl, M., Kantarjian, H., Konopleva, M., Korchin, B., Kaluarachchi, K., Bornmann, W., Duvvuri, S., Taegtmeyer, H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci38942 · Cited by 709
Self-citationLuo, B., & Lee, A. S. (2013) · Oncogene · doi:10.1038/onc.2012.130 · Cited by 560
Cancer stem cells: advances in knowledge and implications for cancer therapy
Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 553
Metadata
- Authors
- Konopleva, M., Zhao, S., Hu, W., Jiang, S., Snell, V., Weidner, D., Jackson, C. E., Zhang, X., Champlin, R., Estey, E., Reed, J. C., & Andreeff, M.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2002-07-25
- Volume
- 118
- Issue
- 2
- Pages
- 521-534
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2154632957
- Cited by
- 171
- References
- 2
- FWCI
- 1.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The anti‐apoptotic genes Bcl‐XL and Bcl‐2 are over‐expressed and contribute to chemoresistance of non‐proliferating leukaemic CD34+ cells. https://app.cochat.ai/papers/10.1046/j.1365-2141.2002.03637.x
- The paper
- Konopleva, M., Zhao, S., Hu, W., Jiang, S., Snell, V., Weidner, D., Jackson, C. E., Zhang, X., Champlin, R., Estey, E., Reed, J. C., & Andreeff, M. (2002). The anti‐apoptotic genes Bcl‐XL and Bcl‐2 are over‐expressed and contribute to chemoresistance of non‐proliferating leukaemic CD34+ cells. British Journal of Haematology. https://doi.org/10.1046/j.1365-2141.2002.03637.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.